YIELD10 BIOSCIENCE, INC.

YTENQ

Explore Our Financial Data > Companies > Cambridge, Massachusetts Companies > YIELD10 BIOSCIENCE, INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	YTENQ
CIK	0001121702
SIC	100
Sector	Agriculture, Forestry, And Fishing
Industry Category	Agriculture
Industry Group	Agricultural Production – Crops

Contact

Address	19 PRESIDENTIAL WAY, SUITE 201, WOBURN, MA, 01801
Website	yield10bio.com
Phone	617-583-1700
CEO	Oliver P. Peoples
Employees	30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$750,000.00
Pre-Tax Income	$-12.70 million
Net Income	$-12.70 million
Net Income to Common	$-12.70 million
EPS	$-19.77

View All

Balance Sheet

Cash	$733,000.00
Assets	$2.97 million
Liabilities	$9.21 million
Common Equity	$-6.24 million
Liabilities & Equity	$2.97 million

View All

Cash Flow Statement

Net Income	$-12.70 million
Cash From Operating Activities	$-5.80 million
Cash From Investing Activities	$-19,000.00
Cash From Financing Activities	$3.98 million
Change in Cash	$-1.86 million

View All

Calculations

NOPAT	$-8.82 million
EBITDA	$-12.43 million
Price to Earnings	N/A
Price to Book	N/A
ROE	203.62%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Yield10 Bioscience Announces First Quarter 2024 Financial Results

-Earns $1 million in milestone payments from Vision Bioenergy OilseedsWOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acid

Article Link

Yield10 Bioscience Announces Delisting from Nasdaq

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maint

Article Link

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split

WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on T

Article Link

Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript

Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript April 1, 2024 Yield10 Bioscience, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.11. Yield10 Bioscience, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]

Article Link

Form DEF 14A YIELD10 BIOSCIENCE, INC. For: Apr 26

Filed on: April 4, 2024.

Article Link